Differential effects of erythropoietin in breast cancer line MCF-7.

LOMBARDI MARIA GABRIELA; SALEM AGUSTINA REINA; MARTINEZ PULIDO PAOLA; DMYTRENKO GANNA; DIEZ ROBERTO A; SALES MARÍA ELENA

Londres

Congreso; British Society of Pharmacology (BSP) meeting; 2015

British Society of Pharmacology

Erythropoietin (EPO) is a pleiotropic cytokine, originally identified for its role in the genesis of red blood cells, promoting survival, proliferation and differentiation of erythrocyte precursors. EPO is also able to stimulate the survival and/or proliferation of different non-erythroid cells. EPO receptor (EPOR) was identified in breast cancer biopsies but not in normal breast tissues (1).The treatment of cancer patients with human recombinant EPO (hrEPO) reduces transfusion requirements and improves quality of life of anemic patients receiving chemotherapy. In spite of this, EPO treatment may have negative effects on patients with breast cancer, since EPO could promote tumor progression through EPOR activation. These receptors were detected in different human breast adenocarcinoma cell lines, like MCF-7 cells (1). Published data demonstrated that although, the stimulation of breast cancer cells with hrEPO resulted in changes in cell signaling mediators such as, AKT, ERK1/2 and STAT5 did not modify cell proliferation or survival rate (2). Taking into account that, these previous results remain controversial, we analyze the effect of hrEPO on MCF-7 cell proliferation, apoptosis and STAT5 signaling. We also used EPO-dependent UT7 erythroleukemic cells as a positive control. Data are given as mean±SEM and the analysis of data was performed using one way ANOVA followed by Tukey test, as applicable. By MTT assay, we observed that the stimulation of MCF-7 cells with hrEPO during 96h significantly increased cell proliferation (1U/ml:1.5±0.2 fold, p